DMRADamora Therapeutics, Inc.
$21.12+92% 1Y
$21.12
$4.9552 weeks$34.14
Is the price fair?
What DMRA's price assumes
Damora Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 194× revenue.
194
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 3.08
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 3.08
- EV / EBIToperating margin −3312%: the multiple describes the denominator
- not meaningful
- Market capitalisation61.7 million shares, counted Aug 7, 2026
- $1.30B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.